Importantly, current clinical interventions for PD (biocompatible PDFs, glucose-sparing regimens, icodextrin, ACEi/ARB, SGLT2 inhibitors in early CKD, and peritonitis prevention bundles) directly target mechanisms of PD membrane damage (inflammation, fibrosis, angiogenesis) or indirectly improve the peritoneal microenvironment to protect the PD membrane, yet they still have clear limitations. The gene discussed is SLC5A2; the disease is peritonitis.